EUVIMEDEUVIMED entdecken
Crossref

Bidirectional regulatory roles of COMMD1 in tumorigenesis and progression: Translational prospects as a diagnostic and therapeutic target (Review)

Wei Lin, Liumin Yu, Rui Shi, Kehao Huang, Zhonghui Chen, Jinqiu Li, Xiaojie Jiang

Oncology Reports · 18.11.2026 · 57 (1) · 1-11

DOI: 10.3892/or.2026.9224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Reports, online erschienen am 18.11.2026. Verfasst von Wei Lin und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Copper metabolism MURR1 domain‑containing protein 1 (COMMD1) is one of the best‑characterised members of the COMMD protein family. Initially identified as a key regulator of copper ion homeostasis, accumulating evidence has shown that COMMD1 does not function as a canonical tumour suppressor or oncogene in malignant tumours. Instead, it serves as a context‑dependent molecular hub whose activity is dynamically influenced by cellular background, signalling pathway status and post‑translational modifications. On the one hand, COMMD1 exerts antitumour effects by inhibiting NF‑κB and hypoxia‑inducible factor‑1 signalling, regulating DNA damage repair, modulating cell cycle progression and enhancing apoptotic sensitivity. Conversely, in certain tumour types, COMMD1 may promote drug resistance and adaptive tumour evolution by preserving DNA repair capacity, supporting cell survival or modulating ubiquitination networks. This review systematically summarises the differential expression patterns and functional mechanisms of COMMD1 in lung cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, multiple myeloma, neuroblastoma and breast cancer, with particular emphasis on its pivotal roles in the inflammatory immune microenvironment, hypoxic adaptation, genomic stability and drug sensitivity. Furthermore, translational strategies targeting COMMD1 are discussed, including COMMD1‑dependent peptide therapeutics, small‑molecule stabilisers, copper chelation‑based combination therapies and gene regulatory interventions. Collectively, the evidence supports COMMD1 as a potential integrated diagnostic and therapeutic target in precision oncology. However, its tissue‑specific and bidirectional functions highlight the need for further mechanistic investigation and patient stratification to enable precise clinical translation.

Zitieren

APA

Lin, W., Yu, L., Shi, R., Huang, K., Chen, Z., Li, J., & Jiang, X. (2026). Bidirectional regulatory roles of COMMD1 in tumorigenesis and progression: Translational prospects as a diagnostic and therapeutic target (Review). Oncology Reports, 57(1), 1-11. https://doi.org/10.3892/or.2026.9224

Vancouver

Lin W, Yu L, Shi R, Huang K, Chen Z, Li J, et al. Bidirectional regulatory roles of COMMD1 in tumorigenesis and progression: Translational prospects as a diagnostic and therapeutic target (Review). Oncology Reports. 2026;57(1):1-11. doi:10.3892/or.2026.9224

BibTeX
@article{Lin2026,
  author = {Lin, Wei and Yu, Liumin and Shi, Rui and Huang, Kehao and Chen, Zhonghui and Li, Jinqiu and Jiang, Xiaojie},
  title = {Bidirectional regulatory roles of COMMD1 in tumorigenesis and progression: Translational prospects as a diagnostic and therapeutic target (Review)},
  journal = {Oncology Reports},
  year = {2026},
  volume = {57},
  number = {1},
  pages = {1--11},
  doi = {10.3892/or.2026.9224}
}
Kostenlos starten →